Byterna Therapeutics
Contact Us
← All news & publications

JUL 2026 · FINANCING

Pre-A financing completed

The financing supports BR101 development and continued investment in Byterna’s personalized cancer-vaccine and programmable mRNA capabilities.

BYTERNA / FINANCING MILESTONE

STRATEGIC MOMENTUM FOR RNA MEDICINES

Pre-Afinancing completed.

OUR INVESTORS

Insilico Medicine logoInsilico MedicineLead investor
Efung Capital logoEfung CapitalContinued investment

Byterna announced the completion of a Pre-A financing round led by Insilico Medicine, with continued investment from Efung Capital.

The company stated that proceeds would support BR101, its personalized circular mRNA cancer-vaccine pipeline and continued development of an AI-enabled mRNA R&D system.